Positron Emission Tomography (PET) is transforming the medical imaging landscape with its ability to detect, measure, and monitor physiological functions at a molecular level. From diagnosing cancers and cardiovascular diseases to evaluating brain disorders like Alzheimer’s and Parkinson’s, PET imaging has become an indispensable diagnostic tool. But with advancing technologies, broader clinical applications, and supportive healthcare policies, the big question is: Can the PET market maintain its strong growth momentum through 2034?
According to industry estimates, the global PET market was valued at USD 2.67 billion in 2024 and is projected to reach USD 4.44 billion by 2034, expanding at a CAGR of 6.60% (2025–2034).
Key factors fueling this growth include:
Expanding use in cardiology and neurology.
Rising burden of cancer and chronic diseases.
Availability of advanced radiopharmaceuticals and tracers.
Strong investments in hybrid imaging technologies such as PET/CT and PET/MRI.
Access a Sample Report with Full TOC and Figures @ https://www.zionmarketresearch.com/sample/positron-emission-tomography-market
PET is increasingly used in myocardial perfusion imaging, offering superior diagnostic accuracy over SPECT. In neurology, PET assists in the early detection of cognitive impairments and supports biomarker-guided care for conditions like Alzheimer’s disease. The rising demand in these domains is driving PET adoption globally.
Healthcare guidelines now recommend PET for multiple cancers, including lymphoma, lung, prostate, and neuroendocrine tumors. Expanding reimbursement policies have further reduced patient cost barriers, leading to wider adoption among hospitals and diagnostic centers.
Skilled Workforce Shortage: There is a global lack of trained PET professionals, including radiologists, technologists, and radiopharmacists. This shortage limits service availability and patient throughput.
Tracer Supply Chain Issues: PET radiotracers have short half-lives, requiring on-site or nearby cyclotrons. This increases operational costs and restricts adoption in remote or underdeveloped areas.
Competition from Other Modalities: Cost-effective alternatives such as CT, MRI, and SPECT pose competitive pressure on PET utilization.
Next-Gen Radiotracers: Research on tracers for infectious, cardiovascular, and inflammatory diseases could broaden PET’s clinical applications.
AI-Powered PET Analysis: Artificial Intelligence integration in PET scanning can improve accuracy, reduce interpretation time, and support less experienced radiologists.
Total-Body PET Scanners: With 40x higher sensitivity and ultra-low-dose imaging, these scanners are opening PET to new clinical and research markets, adding significant growth potential.
Mobile & Portable PET Solutions: Enhancing accessibility in rural and underserved areas, especially in North America and APAC.
North America dominates due to strong healthcare infrastructure, high cancer prevalence, and continuous technological innovations.
Europe ranks second, with robust funding, universal healthcare access, and adoption of hybrid PET/CT systems.
Asia Pacific (APAC) is emerging as a high-growth region, driven by healthcare modernization, rising cancer incidence, and government investments in advanced imaging solutions.
By Product Type: Full-ring PET scanners lead due to superior image quality and higher sensitivity.
By Detector Type: Lutetium Yttrium Orthosilicate (LYSO) dominates for its optimal resolution and timing accuracy.
By End Use: Hospitals hold the largest share owing to infrastructure and integration of hybrid PET systems.
Leading players include Siemens Healthineers, GE Healthcare, Philips Healthcare, Canon Medical Systems, United Imaging Healthcare, Hitachi Medical Systems, Mediso, Positron Corporation, Sofie Biosciences, among others. These companies are focusing on digital PET, AI integration, and expanding radiopharmaceutical offerings.
The positron emission tomography (PET) market is entering a high-growth phase fueled by clinical adoption in cardiology and neurology, advancements in hybrid imaging systems, and supportive reimbursement policies. However, workforce shortages, supply chain constraints, and competition from other imaging modalities remain challenges.
Still, with AI-powered diagnostics, novel tracers, and next-gen PET technologies, the industry is well-positioned to expand into new disease areas and geographies. By 2034, PET is expected to evolve from a cancer-focused imaging tool into a multi-disciplinary diagnostic powerhouse, shaping the future of precision medicine.